[Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].
Lidove
Olivier
O
Choukroun
Gabriel
G
Bekri
Soumeya
S
Viot
Géraldine
G
Tsimaratos
Michel
M
Joly
Dominique
D
D000293:Adolescent; D000328:Adult; D001709:Biotechnology; D004335:Drug and Narcotic Control; D056947:Enzyme Replacement Therapy; D005062:European Union; D000795:Fabry Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000600:supply & distribution / Q000627:therapeutic use; D008297:Male; D009965:Orphan Drug Production; D000519:alpha-Galactosidase / Q000600:supply & distribution / Q000627:therapeutic use*
D007527:Isoenzymes; D000519:alpha-Galactosidase; C459420:agalsidase beta